These MOAs manifested in in vivo antitumor activities of TAVO412 in a diverse panel of NSCLC tumor models with varying EGFR mutations, a broad range of EGFR and cMET receptor densities, and VEGF secretion levels. Here, VEGFA is linked to neoplasm.